PT4313058T - Composição que compreende roginolisib e regime de dosagem para tratar cancro ou uma doença inflamatória ou autoimune - Google Patents
Composição que compreende roginolisib e regime de dosagem para tratar cancro ou uma doença inflamatória ou autoimuneInfo
- Publication number
- PT4313058T PT4313058T PT227192663T PT22719266T PT4313058T PT 4313058 T PT4313058 T PT 4313058T PT 227192663 T PT227192663 T PT 227192663T PT 22719266 T PT22719266 T PT 22719266T PT 4313058 T PT4313058 T PT 4313058T
- Authority
- PT
- Portugal
- Prior art keywords
- pi3k
- treatment regimens
- delta inhibitor
- delta
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2104416.9A GB202104416D0 (en) | 2021-03-29 | 2021-03-29 | Treatment reginmens |
| GBGB2117511.2A GB202117511D0 (en) | 2021-12-03 | 2021-12-03 | Treatment regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT4313058T true PT4313058T (pt) | 2025-06-02 |
Family
ID=81388915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT227192663T PT4313058T (pt) | 2021-03-29 | 2022-03-29 | Composição que compreende roginolisib e regime de dosagem para tratar cancro ou uma doença inflamatória ou autoimune |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12605389B2 (https=) |
| EP (1) | EP4313058B1 (https=) |
| JP (1) | JP7839803B2 (https=) |
| AU (1) | AU2022251843B2 (https=) |
| CA (1) | CA3212731A1 (https=) |
| DK (1) | DK4313058T3 (https=) |
| ES (1) | ES3031295T3 (https=) |
| FI (1) | FI4313058T3 (https=) |
| HR (1) | HRP20250516T1 (https=) |
| HU (1) | HUE071610T2 (https=) |
| LT (1) | LT4313058T (https=) |
| MX (1) | MX2023011442A (https=) |
| PL (1) | PL4313058T3 (https=) |
| PT (1) | PT4313058T (https=) |
| RS (1) | RS66754B1 (https=) |
| SI (1) | SI4313058T1 (https=) |
| WO (1) | WO2022207646A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026510567A (ja) * | 2023-03-03 | 2026-04-08 | アイオンクチュラ・ソシエテ・アノニム | 血液悪性腫瘍の治療におけるロギノリシブ及びｂｃｌ－２阻害剤の組み合わせ |
| AU2024231699A1 (en) * | 2023-03-03 | 2025-09-11 | Ionctura Sa | Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201290305A1 (ru) | 2009-11-13 | 2012-12-28 | Мерк Сероно С.А. | Производные трициклического пиразоламина |
| WO2014121901A1 (en) | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Polymorphic forms |
| US9986723B2 (en) | 2014-10-22 | 2018-06-05 | The Board Of Regents Of The University Of Texas System | Screen and use of therapeutics for pancreatic ductal adenocarcinoma |
| GB201502020D0 (en) | 2015-02-06 | 2015-03-25 | Cancer Rec Tech Ltd | Autotaxin inhibitory compounds |
| EP3610264A1 (en) | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
-
2022
- 2022-03-29 WO PCT/EP2022/058283 patent/WO2022207646A1/en not_active Ceased
- 2022-03-29 CA CA3212731A patent/CA3212731A1/en active Pending
- 2022-03-29 AU AU2022251843A patent/AU2022251843B2/en active Active
- 2022-03-29 MX MX2023011442A patent/MX2023011442A/es unknown
- 2022-03-29 HR HRP20250516TT patent/HRP20250516T1/hr unknown
- 2022-03-29 PT PT227192663T patent/PT4313058T/pt unknown
- 2022-03-29 EP EP22719266.3A patent/EP4313058B1/en active Active
- 2022-03-29 DK DK22719266.3T patent/DK4313058T3/da active
- 2022-03-29 HU HUE22719266A patent/HUE071610T2/hu unknown
- 2022-03-29 SI SI202230137T patent/SI4313058T1/sl unknown
- 2022-03-29 FI FIEP22719266.3T patent/FI4313058T3/fi active
- 2022-03-29 PL PL22719266.3T patent/PL4313058T3/pl unknown
- 2022-03-29 LT LTEPPCT/EP2022/058283T patent/LT4313058T/lt unknown
- 2022-03-29 ES ES22719266T patent/ES3031295T3/es active Active
- 2022-03-29 JP JP2023560623A patent/JP7839803B2/ja active Active
- 2022-03-29 US US18/271,196 patent/US12605389B2/en active Active
- 2022-03-29 RS RS20250390A patent/RS66754B1/sr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022251843A1 (en) | 2023-10-05 |
| LT4313058T (lt) | 2025-05-26 |
| US20240058351A1 (en) | 2024-02-22 |
| RS66754B1 (sr) | 2025-05-30 |
| WO2022207646A1 (en) | 2022-10-06 |
| JP2024518685A (ja) | 2024-05-02 |
| US12605389B2 (en) | 2026-04-21 |
| PL4313058T3 (pl) | 2025-06-23 |
| AU2022251843B2 (en) | 2026-04-09 |
| HUE071610T2 (hu) | 2025-09-28 |
| EP4313058A1 (en) | 2024-02-07 |
| ES3031295T3 (en) | 2025-07-07 |
| CA3212731A1 (en) | 2022-10-06 |
| SI4313058T1 (sl) | 2025-07-31 |
| EP4313058B1 (en) | 2025-03-05 |
| FI4313058T3 (fi) | 2025-04-30 |
| MX2023011442A (es) | 2023-10-18 |
| JP7839803B2 (ja) | 2026-04-02 |
| HRP20250516T1 (hr) | 2025-06-20 |
| DK4313058T3 (da) | 2025-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202105747XA (en) | Csf1r inhibitors for use in treating cancer | |
| SI3704108T1 (sl) | Inhibitor irak4 v kombinaciji z inhibitorjem bcl-2 za uporabo pri zdravljenju raka | |
| IL277629A (en) | RET inhibitor for use in the treatment of cancer involving a change in RET | |
| SG11202105192WA (en) | Radioimmunoconjugates and dna damage and repair inhibitor combination therapy | |
| SG11202011261PA (en) | Urolithin a and derivatives thereof for use in therapy | |
| HUE058323T2 (hu) | Egy BTK-inhibitor rák kezelésében történõ alkalmazásra | |
| PT4313058T (pt) | Composição que compreende roginolisib e regime de dosagem para tratar cancro ou uma doença inflamatória ou autoimune | |
| GB2613497B (en) | Enhanced scale inhibitor squeeze treatment using a chemical additive | |
| ZA202007955B (en) | Ccr5 inhibitor for use in treating cancer | |
| IL315886A (en) | Dosing regimens for anti-CD19 agents and their uses | |
| ZA202205794B (en) | Once daily cancer treatment regimen with a prmt5 inhibitor | |
| IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
| IL286949A (en) | Mesitantan for use in the treatment of portopulmonary hypertension | |
| IL306046A (en) | A preparation for use in the treatment of disorders related to MHC-1 | |
| IL316378A (en) | PI3Kα inhibitors | |
| GB202020607D0 (en) | Apparatus for use in a liquid pool | |
| GB202117511D0 (en) | Treatment regimens | |
| HK40116642A (en) | Cancer treatment using ketotifen in combination with a checkpoint inhibitor | |
| GB202110150D0 (en) | Compounds useful in therapy | |
| PL3965954T3 (pl) | Napęd przedmiotu obrabianego i urządzenie do usuwania zgorzelin z napędem przedmiotu obrabianego | |
| IL313756A (en) | Inhibitors of the sestrin-MAPK complex | |
| GB201912159D0 (en) | A composition for use in treating fibromyalgia | |
| GB202112635D0 (en) | Treatment regimen | |
| HK40106248A (en) | A composition for use in treating mhc-1-opathies | |
| GB202212963D0 (en) | Treatment regimen |